Angiotensin-Converting Enzyme Inhibitors-Beneficial Effects Seen in Many Patient Groups May Not Extend to Kidney Transplant Recipients

Transplantation. 2016 Mar;100(3):472-3. doi: 10.1097/TP.0000000000001140.

Authors

Nicholas B Cross¹, Angela C Webster

Affiliation

¹ 1 Department of Nephrology, Canterbury District Health Board, Christchurch, New Zealand. 2 Department of Medicine, Otago University, Christchurch, New Zealand. 3 Sydney School of Public Health, University of Sydney, NSW, Australia. 4 Centre for Transplant Renal Research, Westmead Hospital, Westmead, NSW, Australia.

PMID: 26900806
DOI: 10.1097/TP.0000000000001140

No abstract available

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Calcium Channel Blockers / therapeutic use
Evidence-Based Medicine
Humans
Hypertension / diagnosis
Hypertension / drug therapy*
Hypertension / etiology
Hypertension / physiopathology
Kidney Transplantation / adverse effects*
Patient Selection
Proteinuria / etiology
Randomized Controlled Trials as Topic
Renal Insufficiency, Chronic / complications
Renal Insufficiency, Chronic / diagnosis
Renal Insufficiency, Chronic / surgery*
Treatment Outcome

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Calcium Channel Blockers